Active, not recruitingPhase 3NCT05417789
Study of Emactuzumab for Tenosynovial Giant Cell Tumor (TGCT)
Studying Tenosynovial giant cell tumor
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- SynOx Therapeutics Limited
- Principal Investigator
- Jean Y Blay, Prof, MDComprehensive Cancer Centre of Lyon
- Intervention
- Emactuzumab(drug)
- Enrollment
- 128 target
- Eligibility
- 12 years · All sexes
- Timeline
- 2024 – 2027
Study locations (30)
- NextGen Oncology, Beverly Hills, California, United States
- Sarcoma Oncology Research Center, LLC, Los Angeles, California, United States
- USC Norris Comprehensive Cancer Center, Los Angeles, California, United States
- University of Kansas Cancer Center (Overland Park) - USOR, Overland Park, Kansas, United States
- University of Minnesota, Minneapolis, Minnesota, United States
- Duke Cancer Center, Durham, North Carolina, United States
- The Ohio State University, Columbus, Ohio, United States
- OHSU Knight Cancer Institute Hematology Oncology, Portland, Oregon, United States
- MD Anderson Cancer Center, Houston, Texas, United States
- MedStar Washington Hospital Center, Georgetown, Washington, United States
- LKH-Universitätsklinikum Graz, Graz, Austria
- Cliniques Universitaires Saint-Luc, Woluwe-Saint-Lambert, Brussels Capital, Belgium
- UZ Gent - Department of Medical Oncology, Ghent, Belgium
- Arthur J.E. Child Comprehensive Cancer Centre, Calgary, Alberta, Canada
- Princess Margaret Cancer Centre, Toronto, Ontario, Canada
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05417789 on ClinicalTrials.govOther trials for Tenosynovial giant cell tumor
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07499362Study of Pimicotinib in Japanese Participants With Tenosynovial Giant Cell Tumor (TGCT) (J-MANEUVER)Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
- RECRUITINGPHASE4NCT07315841Accuracy of Indocyanine Green (ICG) Fluorescence Imaging in Tenosynovial Giant Cell Tumor SurgeryShanghai Jiao Tong University Affiliated Sixth People's Hospital
- RECRUITINGNCT07075471Tenosynovial Giant Cell Tumor (TGCT) Real-World Participant Experience With VimseltinibDeciphera Pharmaceuticals, LLC
- ACTIVE NOT RECRUITINGPHASE3NCT05804045Study of Pimicotinib (ABSK021) for Tenosynovial Giant Cell Tumor (MANEUVER)Abbisko Therapeutics Co, Ltd
- ACTIVE NOT RECRUITINGPHASE3NCT05059262Study of Vimseltinib for Tenosynovial Giant Cell TumorDeciphera Pharmaceuticals, LLC
- ACTIVE NOT RECRUITINGPHASE2NCT04703322A Study of Pexidartinib in Tenosynovial Giant Cell Tumor in JapanDaiichi Sankyo Co., Ltd.
- RECRUITINGNCT04635111A Long-term Study Evaluating Hepatotoxicity Associated With TURALIO™ (Pexidartinib) TreatmentDaiichi Sankyo
- ACTIVE NOT RECRUITINGPHASE3NCT04488822A Study of the Efficacy and Safety of Pexidartinib in Adult Subjects With TGCTDaiichi Sankyo Co., Ltd.